Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1159-1161

  Hsu, Chih Hung ^a,b   Chen, Mao Yuan ^a   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Kaposi's sarcoma (KS); Paclitaxel

Indexed keywords

BLEOMYCIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; HUMAN; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PACLITAXEL; RANITIDINE; SARCOMA, KAPOSI;

EID: 0034054140     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Miles SA, Mitsuyasu Rl, Aboulafia DM: AIDS-related malignancies. In: DeVita VT, Hellman S, and Rosenberg SA, eds: Cancer: Principles & Practice of Oncology. 5th ed. Philadelphia: Lippicott-Raven Publishers; 1997: 2445-2449.
2. Lee FC, Mitsuyasu RT: Chemotherapy of AIDS-related Kaposi's sarcoma. Hematol/Oncol Clin North Am 10: 1051-1068, 1996.
3. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, Yarchoan R: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346: 26-28, 1995.
4. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus- associated Kaposi's sarcoma. J Clin Oncol 16: 1112-1121, 1998.
5. Fennelly D, Aghajanian C, Shapiro F, O'flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 5: 187-192, 1497.
6. Kalssen U, Wilke H, Strumberg D, Eberhardt W, Korn M, Seeber S: Phase 1 study with a weekly 1-hour infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A: 547-549, 1996.
7. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Maynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998.
8. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J. O'Shaughnessy J, Balis FM, Chabner BA: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion, J Clin Oncol 12: 1621-1629, 1994.
9. Lopes NM, Adams EF, Pitts TW, Bhuyan BK: Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235-242, 1993.
10. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996.